Randomized controlled trial of Low level laser therapy and magnetotherapy as coadjuvant in Bisphosphonate related osteonecrosis of the jaws treatment

niversidade Nove de Julho0 个研究点开始时间: 2020年4月22日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Consent to participate in the study through a Free and Informed Consent Form signed by the patient, female, 60 years of age or older, using oral Alendronate sodium, with weekly doses of 70mg for at least 2 years. continuously for the prevention and or treatment of osteopenia or osteoporosis.
•Presence of jaw osteonecrosis, in stages 1 or 2, according to the AAOMS classification. Patients who have previously undergone oral cavity surgical procedures, such as dental extractions or implants, performed no more than 6 months prior to the occurrence of osteonecrosis.

•Presence of jaw osteonecrosis at stage 0 or 3, according to AAOMS.
•Presence of spontaneous osteonecrosis in the jaws.
•Pathological fractures by osteonecrosis.
•Use of alendronate for less than two years or discontinued.
•Need to use synthesis material (plate and screws).
•Indication of the use of alendronate sodium due to malignant neoplasms, bone metastases, Paget's disease or any indication other than osteoporosis or osteopenia.
•Patients undergoing head and neck radiotherapy in the last 5 years.
•Patients undergoing hyperbaric chamber sessions in the last 2 years.
•Patients with blood dyscrasias, renal failure, liver failure, cardio respiratory failure, immune deficiency, malignant neoplasms, AIDS or septicemia.

发起方

niversidade Nove de Julho